Rhumbline Advisers Exelixis, Inc. Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Exelixis, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 889,688 shares of EXEL stock, worth $19.7 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
889,688
Previous 944,776
5.83%
Holding current value
$19.7 Million
Previous $22.7 Million
6.85%
% of portfolio
0.02%
Previous 0.02%
Shares
27 transactions
Others Institutions Holding EXEL
# of Institutions
460Shares Held
246MCall Options Held
1.7MPut Options Held
1.02M-
Black Rock Inc. New York, NY34.9MShares$773 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA30.8MShares$683 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA26.7MShares$591 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.1MShares$335 Million0.56% of portfolio
-
State Street Corp Boston, MA13.1MShares$290 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $7.13B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...